Hepatic Artery Infusional Floxuridine to Treat Pancreatic Cancer Liver Metastases
Status:
Recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
This is a single arm, phase II study without blinding. The purpose is to determine the impact
of hepatic artery infusion Floxuridine (FUDR) on liver metastases from pancreatic
adenocarcinoma. Patients at Spectrum Health will receive standard of care chemotherapy. They
will also receive chemotherapy via surgically placed hepatic artery infusion (HAI) pump.